These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 11405346)

  • 1. Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy.
    Platt FM; Jeyakumar M; Andersson U; Priestman DA; Dwek RA; Butters TD; Cox TM; Lachmann RH; Hollak C; Aerts JM; Van Weely S; Hrebícek M; Moyses C; Gow I; Elstein D; Zimran A
    J Inherit Metab Dis; 2001 Apr; 24(2):275-90. PubMed ID: 11405346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substrate deprivation: a new therapeutic approach for the glycosphingolipid lysosomal storage diseases.
    Platt FM; Butters TD
    Expert Rev Mol Med; 2000 Feb; 2(1):1-17. PubMed ID: 14585134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substrate reduction therapy for glycosphingolipid storage disorders.
    Lachmann RH; Platt FM
    Expert Opin Investig Drugs; 2001 Mar; 10(3):455-66. PubMed ID: 11227045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.
    Jeyakumar M; Butters TD; Dwek RA; Platt FM
    Neuropathol Appl Neurobiol; 2002 Oct; 28(5):343-57. PubMed ID: 12366816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New therapeutic prospects for the glycosphingolipid lysosomal storage diseases.
    Platt FM; Butters TD
    Biochem Pharmacol; 1998 Aug; 56(4):421-30. PubMed ID: 9763217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.
    Andersson U; Smith D; Jeyakumar M; Butters TD; Borja MC; Dwek RA; Platt FM
    Neurobiol Dis; 2004 Aug; 16(3):506-15. PubMed ID: 15262262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin.
    Jeyakumar M; Butters TD; Cortina-Borja M; Hunnam V; Proia RL; Perry VH; Dwek RA; Platt FM
    Proc Natl Acad Sci U S A; 1999 May; 96(11):6388-93. PubMed ID: 10339597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases.
    Butters TD; Dwek RA; Platt FM
    Adv Exp Med Biol; 2003; 535():219-26. PubMed ID: 14714898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuronal Ganglioside and Glycosphingolipid (GSL) Metabolism and Disease : Cascades of Secondary Metabolic Errors Can Generate Complex Pathologies (in LSDs).
    Sandhoff R; Sandhoff K
    Adv Neurobiol; 2023; 29():333-390. PubMed ID: 36255681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation.
    Jeyakumar M; Norflus F; Tifft CJ; Cortina-Borja M; Butters TD; Proia RL; Perry VH; Dwek RA; Platt FM
    Blood; 2001 Jan; 97(1):327-9. PubMed ID: 11133779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses.
    Butters TD; Dwek RA; Platt FM
    Glycobiology; 2005 Oct; 15(10):43R-52R. PubMed ID: 15901676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin.
    Platt FM; Neises GR; Reinkensmeier G; Townsend MJ; Perry VH; Proia RL; Winchester B; Dwek RA; Butters TD
    Science; 1997 Apr; 276(5311):428-31. PubMed ID: 9103204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substrate-reduction therapy with miglustat for glycosphingolipid storage disorders affecting the brain.
    Lachmann RH
    Expert Rev Endocrinol Metab; 2009 May; 4(3):217-224. PubMed ID: 30743792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic applications of imino sugars in lysosomal storage disorders.
    Butters TD; Dwek RA; Platt FM
    Curr Top Med Chem; 2003; 3(5):561-74. PubMed ID: 12570866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders.
    Butters TD; Mellor HR; Narita K; Dwek RA; Platt FM
    Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):927-45. PubMed ID: 12803927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substrate reduction therapy for lysosomal storage diseases.
    Cox TM
    Acta Paediatr Suppl; 2005 Mar; 94(447):69-75; discussion 57. PubMed ID: 15895716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder.
    Liu Y; Wada R; Kawai H; Sango K; Deng C; Tai T; McDonald MP; Araujo K; Crawley JN; Bierfreund U; Sandhoff K; Suzuki K; Proia RL
    J Clin Invest; 1999 Feb; 103(4):497-505. PubMed ID: 10021458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysosomal storage of oligosaccharide and glycosphingolipid in imino sugar treated cells.
    Boomkamp SD; Rountree JS; Neville DC; Dwek RA; Fleet GW; Butters TD
    Glycoconj J; 2010 Apr; 27(3):297-308. PubMed ID: 20186478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases.
    Shayman JA; Larsen SD
    J Lipid Res; 2014 Jul; 55(7):1215-25. PubMed ID: 24534703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substrate reduction therapy of glycosphingolipid storage disorders.
    Aerts JM; Hollak CE; Boot RG; Groener JE; Maas M
    J Inherit Metab Dis; 2006; 29(2-3):449-56. PubMed ID: 16763917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.